Sponsor - F. Hoffmann-La Roche Ltd. (Recruitment/Not yet Open)
Study: COMINO GR41986
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASEKD, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION
Sponsor - Kodiak Sciences, Inc. (Recruitment/Not yet Open)
Study: BEACON KS301P103
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Sponsor - Novartis (Open to Enrollment)
Study: RAVEN
An
Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III
study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in
Adult Patients with Visual Impairment due to Macular Edema secondary to Central
Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03810313?term=raven&rank=3
Sponsor - Patrick Higgins, MD (Recruitment/Open to Enrollment)
Study: IST
Retrospective chart review of the prevalence of positive findings in the hypercoagulability workup on patients with ischemic and nonischemic retinal vein occlusions
Previous Central Retinal Vein Occlusion (CRVO) Study:
Sub-Investigator, 2008 - 2010
Sponsor: Genentech
Study: HORIZON
An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Ranibizumab Study
Sub-Investigator, 2007 - 2010
Sponsor: Genentech
Study: CRUISE
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT00485836?term=CRUISE&rank=1